UBS Group’s Instil Bio TIL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$52.6K Buy
6,378
+6,019
+1,677% +$48.8K ﹤0.01% 7341
2025
Q4
$3.95K Sell
359
-5,262
-94% -$77.8K ﹤0.01% 8914
2025
Q3
$100K Sell
5,621
-10,598
-65% -$269K ﹤0.01% 7128
2025
Q2
$338K Sell
16,219
-1,061
-6% -$22.2K ﹤0.01% 6347
2025
Q1
$300K Sell
17,280
-73,806
-81% -$1.53M ﹤0.01% 6241
2024
Q4
$1.74M Buy
91,086
+90,955
+69,431% +$2.77M ﹤0.01% 4855
2024
Q3
$8.82K Buy
131
+99
+309% +$2.33K ﹤0.01% 7819
2024
Q2
$329 Sell
32
-227
-88% -$2.45K ﹤0.01% 8977
2024
Q1
$2.8K Buy
259
+138
+114% +$1.51K ﹤0.01% 7826
2023
Q4
$922 Buy
121
+100
+476% +$723 ﹤0.01% 8475
2023
Q3
$182 Buy
21
+1
+5% +$10 ﹤0.01% 8737
2023
Q2
$224 Sell
20
-1,246
-98% -$15.2K ﹤0.01% 8368
2023
Q1
$16.7K Buy
1,266
+293
+30% +$4.33K ﹤0.01% 7216
2022
Q4
$12.3K Buy
973
+957
+5,981% +$47.3K ﹤0.01% 8296
2022
Q3
$1K Buy
+16
New +$1.83K ﹤0.01% 10040
2022
Q2
Sell
-1
Closed 10940
2022
Q1
$0 Sell
1
-527
-100% -$123K ﹤0.01% 10894
2021
Q4
$181K Buy
+528
New +$204K ﹤0.01% 5787
2021
Q3
Sell
-36
Closed -$14K 10081
2021
Q2
$14K Buy
+36
New +$13.4K ﹤0.01% 7718

Other funds holding TIL

UBS Group's TIL Position: Q1 2026 in Review

UBS Group increased its Instil Bio (TIL) stake by 1,677% in Q1 2026, buying an estimated $48.8K and bringing the position to 6,378 shares worth $52.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7341.

UBS Group first reported a position in TIL in Q2 2021 and has held it in 18 quarters since. The position peaked at $1.74M in Q4 2024. 32 funds tracked by Wall St. Rank hold TIL as of Q1 2026.

  • UBS Group held 6,378 shares of Instil Bio worth $52.6K as of Q1 2026.
  • UBS Group bought 6,019 Instil Bio shares in Q1 2026, an estimated $48.8K.
  • Instil Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7341 holding.
  • UBS Group first reported a position in Instil Bio in Q2 2021 and has held it in 18 quarters since.
  • UBS Group's Instil Bio position peaked at $1.74M in Q4 2024.
  • 32 funds tracked by Wall St. Rank held Instil Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.